At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 281 enrolled
Drug / intervention
SUNPG18_07 I (Tildrakizumab 200 mg) +1 moredrug
Likely dose
SUNPG18_07 I (Tildrakizumab 200 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
In Brief
A Phase 3 clinical trial evaluating SUNPG18_07 I (Tildrakizumab 200 mg) and SUNPG18_07 II (Tildrakizumab 100 mg) for Psoriatic Arthritis. Completed, enrolled 281 participants across 66 sites in 8 countries.
Detailed Summary
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesArgentina, Hungary, Mexico, Poland, Russia, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionSep 2023
TodayJul 2026
First PostedJun 11, 2018
Enrollment StartJul 11, 2018
Primary CompletionSep 18, 2023
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 8.1 years ago
Interventions
SUNPG18_07 I (Tildrakizumab 200 mg)drug
injection
SUNPG18_07 II (Tildrakizumab 100 mg)drug
injection